Paysign, Inc.
5.44-0.30 (-5.23%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · PAYS · USD
Key Stats
Market Cap
296.22MP/E (TTM)
45.33Basic EPS (TTM)
0.12Dividend Yield
0%Recent Filings
8-K
Paysign settles derivative suits
Paysign settled derivative lawsuits alleging fiduciary breaches from 2019-2020 IT control failures and misleading disclosures, which delayed its 10-K filing. The deal mandates five-year corporate governance reforms, including new IT and disclosure committees, auditor rotation, and enhanced whistleblower policies, while insurers cover $607,500 in plaintiffs' fees. Reforms promise stronger oversight. Litigation ends November 14, 2025.
10-Q
Q2 FY2025 results
Paysign's Q2 revenue climbed 33.1% year-over-year to $19.1M, propelled by a 189.9% surge in pharma industry sales to $7.8M from new patient affordability programs, despite a 4.7% dip in plasma revenue to $10.7M as donations normalized. Gross margin expanded to 61.6% from 52.9%, fueling operating income of $1.4M—up from a slim $0.1M—while diluted EPS held at $0.02 on 57.9M shares. The Gamma acquisition closed March 19, 2025, for $15.6M (cash/equity/contingent), adding $4.5M goodwill and $11.1M intangibles amortized over 9-15 years to boost donor engagement tech. Cash stood at $11.8M with $102.2M restricted; operating cash flow swung to a $2.4M use amid pharma growth timing. Derivative lawsuits linger as a distraction.
8-K
Q2 revenues up 33%, pharma surges
Paysign reported Q2 2025 revenues of $19.1 million, surging 33.1% year-over-year, driven by pharma patient affordability jumping 189.9% to $7.8 million from seven new programs, while plasma dipped 4.7% amid industry oversupply despite adding 123 centers. Net income doubled to $1.4 million, with Adjusted EBITDA soaring 101.8% to $4.5 million and gross margins expanding to 61.6%. Pharma's momentum offsets plasma weakness. Expects 30-40 more programs by year-end.
8-K
Auditor merger prompts resignation
Paysign's auditor Moss Adams resigned on June 3, 2025, following its merger with Baker Tilly US, LLP, which the Audit Committee promptly approved as the new independent accounting firm. No disagreements or reportable events marred the prior audits for 2023 and 2024, ensuring a seamless transition. Clean handover. This administrative shift poses no immediate financial disruptions.
8-K
Annual meeting votes affirm leadership
Paysign stockholders overwhelmingly elected seven directors—Mark R. Newcomer, Matthew Lanford, Joan M. Herman, Bruce A. Mina, Jeffrey B. Newman, Daniel R. Henry, and Dennis L. Triplett—to serve until the 2026 annual meeting, with each receiving over 31 million 'for' votes amid minimal opposition. They endorsed 2025 executive pay on a non-binding basis and favored triennial say-on-pay votes, prompting the board to adopt that cadence. Moss Adams LLP secured ratification as auditors for the year ending December 31, 2025, with near-unanimous support. Governance stays steady.
IPO
Website
Employees
Sector
Industry
CPAY
Corpay, Inc.
268.11-17.48
IPSI
Innovative Payment Solutions, I
0.02-0.00
PAGS
PagSeguro Digital Ltd.
9.50-0.18
PAY
Paymentus Holdings, Inc.
29.42-1.23
PAYC
Paycom Software, Inc.
186.46-12.04
PAYD
Paid, Inc.
3.02+0.00
PAYO
Payoneer Global Inc.
5.87-0.25
PSFE
Paysafe Limited
11.34-0.95
RPAY
Repay Holdings Corporation
4.85-0.35
SMKG
SMART CARD MARKETING SYSTEMS IN
0.01+0.00